Patient-reported outcomes in rheumatic disease patients following COVID-19 infection
| All rheumatic disease patients (N=280) | Breakthrough COVID-19 infection (N=116) | Non-breakthrough COVID-19 infection (N=164) | P value | |
| Pain (SF-MPQ) | ||||
| N | 258 | 111 | 147 | |
| Median score (IQR) | 4 (2–10) | 4 (1–8) | 5 (3–10) | 0.04 |
| Pain rating index ordinal category, n (%) | 0.20 | |||
| No pain | 41 (15) | 17 (15) | 24 (15) | |
| Mild pain | 86 (31) | 43 (37) | 43 (26) | |
| Discomforting, distressing, horrible, or excruciating pain | 135 (48) | 51 (44) | 84 (51) | |
| Fatigue (FSI) | ||||
| N | 264 | 111 | 153 | |
| Median score (IQR) | 54 (26–82) | 48 (21–79) | 55 (28–84) | 0.08 |
| Functional status (mHAQ) | ||||
| N | 270 | 112 | 158 | |
| Median score (IQR) | 0.1 (0.0–0.5) | 0.1 (0.0–0.5) | 0.1 (0.0–0.5) | 0.88 |
| Categorical score, n (%) | 0.61 | |||
| Normal (<0.3) | 163 (58) | 70 (60) | 93 (57) | |
| Mild, moderate, or severe (0.3 to >1.8) | 107 (38) | 42 (36) | 65 (40) | |
| Health status (SF-12) | ||||
| PCS-12 score, median (IQR) | 42.1 (33.0–50.8) | 43.6 (33.7–52.6) | 41.0 (32.2–49.5) | 0.11 |
| MCS-12 score, median (IQR) | 46.8 (36.9–54.4) | 49.3 (41.4–55.6) | 50.2 (37.9–57.0) | 0.86 |
FSI, Fatigue Symptom Inventory; MCS-12, Mental Component Summary score; mHAQ, modified Health Assessment Questionnaire; PCS-12, Physical Component Summary score; SF-12, 12-item Short-Form Health Survey; SF-MPQ, SF McGill Pain Questionnaire.